MK-677 (Ibutamoren) + AOD-9604 Stack: Complete Protocol

What Are MK-677 and AOD-9604, and Why Stack Them?

MK-677 and AOD-9604 work through separate, non-overlapping pathways that together may address both the anabolic and lipolytic sides of body-composition change. MK-677 drives GH secretion from the pituitary and sustains elevated IGF-1 for muscle protein synthesis and recovery. AOD-9604 targets adipose tissue directly, promoting fat breakdown without the glucose-raising properties of full-length growth hormone.

MK-677 (Ibutamoren): Mechanism

MK-677 is a non-peptide ghrelin-receptor agonist taken orally. In a 12-month placebo-controlled trial published in the Journal of Clinical Endocrinology and Metabolism (N=65 obese males), MK-677 25 mg/day increased serum IGF-1 by 60.1% and GH AUC by 82% compared with placebo [1]. Fat-free mass increased by 1.67 kg more than placebo (P<0.001) at 8 weeks, though the effect on fat mass was modest.

Unlike exogenous GH injections, MK-677 preserves the pulsatile pattern of GH secretion. This matters clinically because physiologic GH pulses are associated with less glucose intolerance than continuous GH elevation [2].

AOD-9604 (HGH Fragment 176-191): Mechanism

AOD-9604 is the C-terminal fragment of human growth hormone spanning residues 176-191. Researchers at Monash University identified this region as responsible for HGH's lipolytic activity while being separate from the IGF-1-stimulating domain [3]. In obese rodent models, AOD-9604 reduced body weight by stimulating beta-oxidation of fatty acids and inhibiting lipogenesis, without detectable changes in blood glucose or insulin [3].

Human data are limited. A Phase II trial (NCT00169429) evaluated oral AOD-9604 in overweight adults and reported modest, dose-dependent fat-mass reduction; however, a subsequent Phase IIb/III program did not demonstrate statistically significant weight loss sufficient for FDA approval, and Metabolic Pharmaceuticals discontinued development [4]. The compound received FDA GRAS (Generally Recognized as Safe) designation for use as a food ingredient at low doses, which is frequently misrepresented online as an approval for therapeutic use, it is not [4].

Why Combine the Two

The rationale is additive rather than synergistic in the strict pharmacological sense. MK-677 raises GH and IGF-1, supporting lean mass accrual and recovery. AOD-9604 targets fat stores through a pathway independent of IGF-1. Using them together theoretically addresses both endpoints simultaneously without doubling glucose-disrupting exposure, since AOD-9604 does not raise blood sugar.

Practitioners who use this stack clinically report that the combination works best in individuals who are already lean (body fat 18-28%) and are resistance training consistently, rather than as a standalone weight-loss tool for individuals with significant obesity.

Evidence Base: What the Research Actually Shows

No published randomized controlled trial has evaluated MK-677 and AOD-9604 as a combined stack. The evidence for each agent individually ranges from moderate (MK-677, with several small RCTs) to limited (AOD-9604, with terminated Phase III development). Any claim about the stack's efficacy is extrapolated from individual compound data, mechanistic overlap, and practitioner experience.

MK-677 Clinical Evidence

The strongest MK-677 data come from two controlled trials:

1. Svensson et al. (1998, JCEM, N=24 young men) found MK-677 25 mg/day for 7 days increased 24-hour GH secretion by 97.4% and IGF-1 by 52.4% relative to placebo [1].
2. Murphy et al. (2001, JAGS, N=65 older adults) showed 12 months of MK-677 25 mg/day increased fat-free mass by 1.67 kg (P<0.001) but also raised fasting glucose by 0.3 mmol/L and fasting insulin by 70% above baseline, raising meaningful metabolic safety questions for long-term use [2].

The American Association of Clinical Endocrinology does not currently endorse MK-677 outside investigational settings, noting insufficient long-term cardiovascular and oncologic safety data [5].

AOD-9604 Clinical Evidence

Published human trials for AOD-9604 are sparse. The Monash group's foundational rodent work (Ng et al., Molecular and Cellular Endocrinology, 2000) demonstrated fat-mass reduction without IGF-1 elevation, establishing the mechanistic basis for the compound [3]. Phase I human safety data showed acceptable tolerability at subcutaneous doses up to 400 mcg/day, with no serious adverse events reported in a 12-week observation window [4]. The Phase IIb failure means there is no peer-reviewed, large-scale human efficacy confirmation.

Evidence Gap Summary

| Question | MK-677 Evidence | AOD-9604 Evidence | |---|---|---| | Raises GH/IGF-1 | Yes, RCT-confirmed | No (by design) | | Reduces fat mass | Inconsistent across trials | Rodent yes; human Phase III failed | | Preserves lean mass | Yes, short-term RCT data | Unknown in humans | | Long-term safety | <24 months data only | <12 weeks Phase I only | | Stack combination | No data | No data |

Dosing Protocol

The protocol below represents the most commonly reported practitioner-guided approach. It is not an FDA-approved regimen and should only be undertaken under physician supervision with baseline and follow-up labs.

MK-677 Dosing

Start at 10 mg orally each night, taken 30-60 minutes before sleep. The nighttime timing aligns MK-677's GH-stimulating effect with the body's natural nocturnal GH pulse, potentially amplifying total nightly GH output. After 2-4 weeks, dose may increase to 15-25 mg nightly based on tolerance and laboratory response.

Doses above 25 mg/day have not demonstrated additional IGF-1 benefit in published studies and increase the risk of water retention, joint discomfort (from rapid IGF-1 rise), and worsening insulin sensitivity [2].

AOD-9604 Dosing

Standard reported dose: 250-300 mcg subcutaneously once daily, administered in a fasted state 30-60 minutes before the first meal or morning training session. Fasted administration is preferred because elevated insulin blunts beta-adrenergic fat-oxidation signaling, which may reduce AOD-9604's lipolytic effect.

Injection sites: abdomen, lateral thigh, or lateral deltoid, rotating sites daily. Use a 29-31 gauge insulin syringe; reconstitute lyophilized powder with bacteriostatic water per the supplier's reconstitution guide and store at 2-8°C after reconstitution.

Cycle Length

• AOD-9604: 8-12 weeks, with a 4-week off-period before repeating.
• MK-677: 12-16 weeks is most commonly reported; some protocols run 6 months continuously, though no safety data beyond 24 months exist.

When stacking, align start dates so both compounds run concurrently. A common structure is 12 weeks on both, 4-6 weeks off both, then reassess labs.

Suggested Monitoring Schedule

| Timepoint | Labs to Order | |---|---| | Baseline (before starting) | IGF-1, fasting glucose, fasting insulin, HbA1c, lipid panel, CBC, CMP | | Week 4 | Fasting glucose, fasting insulin, IGF-1 | | Week 8 | Full repeat of baseline panel | | Week 12 (end of cycle) | Full repeat plus DEXA if available | | 4 weeks post-cycle | IGF-1, fasting glucose |

A target IGF-1 of 200-350 ng/mL (age-adjusted upper limit of normal) is a reasonable on-treatment goal. Values above 400 ng/mL should prompt dose reduction or discontinuation.

Side Effects and Safety Considerations

MK-677 Side Effects

The two most clinically relevant adverse effects are increased appetite and insulin resistance. Murphy et al. Documented a 70% rise in fasting insulin over 12 months [2]. For individuals with pre-diabetes or metabolic syndrome, this is a meaningful concern. Water retention (from IGF-1-driven sodium reabsorption) affects roughly 30-50% of users in the first 2-4 weeks and typically resolves. Joint aches from rapid soft-tissue fluid shifts occur in a minority of users.

One additional safety note: MK-677 elevates GH and IGF-1, and there is a theoretical concern about stimulating pre-existing, subclinical malignancy. No causative human data exist, but individuals with a personal or family history of hormone-sensitive cancers should avoid this compound [5].

AOD-9604 Side Effects

Reported adverse effects from Phase I data and post-market practitioner experience are generally mild: transient injection-site redness, mild headache, and occasional nausea in the first week [4]. Because AOD-9604 does not raise IGF-1 or blood glucose, the cardiometabolic risks associated with full-length HGH are not expected. However, the absence of a large safety dataset means rare adverse events cannot be ruled out.

Contraindications for the Stack

• Active malignancy or history of hormone-sensitive cancer
• Type 2 diabetes or HbA1c >5.7% without endocrinologist co-management
• Age <21 (open epiphyses; GH-axis manipulation is inappropriate)
• Pregnancy or breastfeeding
• Current use of insulin or sulfonylureas (additive glucose dysregulation risk with MK-677)

Nutrition and Training Considerations

MK-677's ghrelin-agonist activity substantially increases appetite, often by 20-30% above baseline caloric drive. In a fat-loss protocol, this can undermine the caloric deficit that AOD-9604 depends on for meaningful body-composition change. Addressing this through structured meal timing, adequate protein (minimum 1.6 g/kg/day per current ISSN guidelines), and controlled caloric intake is not optional, it is the variable most likely to determine whether the stack delivers measurable results [6].

Resistance Training

IGF-1 elevation from MK-677 is most productive for lean mass accrual when paired with progressive resistance training 3-5 days per week. Without a training stimulus, elevated IGF-1 does not automatically produce muscle hypertrophy in well-nourished adults [1].

Sleep

MK-677 increases slow-wave sleep duration, which is where a significant portion of endogenous GH pulsatility occurs. A 2008 trial by Copinschi et al. (Sleep, N=14 young men) reported a 20.3% increase in stage IV slow-wave sleep with MK-677 25 mg/day for 7 days [7]. Getting 7-9 hours of sleep per night amplifies this effect and supports recovery.

Regulatory and Sourcing Considerations

Neither MK-677 nor AOD-9604 is FDA-approved for therapeutic use in body composition, anti-aging, or fat loss. Both are classified as research chemicals in the United States. The FDA has issued warning letters to several peptide compounding pharmacies regarding unapproved GH secretagogues, and in 2023 the agency clarified that MK-677 cannot be compounded under 503A or 503B exemptions because it has not been approved as a drug substance [8].

AOD-9604 occupies a more ambiguous position. Its GRAS designation applies to food-ingredient use only, not subcutaneous injection at pharmacological doses [4].

The practical implication: sourcing from an unregulated peptide vendor introduces purity, sterility, and dose-accuracy risks that a physician-supervised compounding pharmacy minimizes. Always request a certificate of analysis (COA) with third-party HPLC confirmation before using any injectable peptide compound.

The Endocrine Society's 2019 Clinical Practice Guideline on growth hormone use states: "We recommend against prescribing GH or GH secretagogues to otherwise healthy adults for anti-aging or body composition purposes outside of a clinical trial setting" [5].

How This Stack Compares to Alternatives

Practitioners considering MK-677 and AOD-9604 often evaluate it against two alternative approaches:

Tesamorelin + CJC-1295/Ipamorelin: Tesamorelin is FDA-approved (Egrifta) for HIV-associated lipodystrophy and has the strongest human body-composition evidence of any GHRH analog. It reduces visceral fat by 15-20% in 26-week trials [9]. CJC-1295/Ipamorelin stacks offer a dual GHRH/GHRP approach with more granular dose control than MK-677. The trade-off is daily injection burden that MK-677's oral route avoids.

Semaglutide (Wegovy) for fat loss: In STEP-1 (N=1,961), semaglutide 2.4 mg weekly produced 14.9% mean body-weight loss at 68 weeks vs. 2.4% with placebo [10]. For individuals whose primary goal is fat loss, the evidence gap between semaglutide and any peptide stack is wide. MK-677 plus AOD-9604 does not approach that magnitude of fat-mass reduction in available data.

The MK-677/AOD-9604 stack occupies a specific niche: individuals who are already lean, actively resistance-training, and seeking modest fat reduction alongside lean-mass support, rather than those with significant obesity or metabolic disease.

Frequently Asked Questions